HK1027806A1 - Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds - Google Patents
Aromatic sulfonyl alpha-hydroxy hydroxamic acid compoundsInfo
- Publication number
- HK1027806A1 HK1027806A1 HK00106978A HK00106978A HK1027806A1 HK 1027806 A1 HK1027806 A1 HK 1027806A1 HK 00106978 A HK00106978 A HK 00106978A HK 00106978 A HK00106978 A HK 00106978A HK 1027806 A1 HK1027806 A1 HK 1027806A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hydroxamic acid
- acid compounds
- aromatic sulfonyl
- acid compound
- sulfonyl alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3518297P | 1997-03-04 | 1997-03-04 | |
PCT/US1998/004277 WO1998039326A1 (fr) | 1997-03-04 | 1998-03-04 | Composes aromatiques d'acide sulfonyle alpha-hydroxy hydroxamique |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1027806A1 true HK1027806A1 (en) | 2001-01-23 |
Family
ID=21881145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00106978A HK1027806A1 (en) | 1997-03-04 | 2000-11-02 | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
Country Status (20)
Country | Link |
---|---|
US (3) | US6380258B2 (fr) |
EP (4) | EP0983258A4 (fr) |
JP (4) | JP2002513407A (fr) |
KR (3) | KR20000075946A (fr) |
CN (3) | CN1105114C (fr) |
AT (1) | ATE254599T1 (fr) |
AU (2) | AU750303B2 (fr) |
BR (2) | BR9808214A (fr) |
CA (4) | CA2282318A1 (fr) |
DE (1) | DE69819878T2 (fr) |
DK (1) | DK0973392T3 (fr) |
EA (1) | EA199900792A1 (fr) |
ES (2) | ES2209122T3 (fr) |
HK (1) | HK1027806A1 (fr) |
IL (3) | IL131493A (fr) |
NO (1) | NO315647B1 (fr) |
NZ (1) | NZ337326A (fr) |
PL (1) | PL335732A1 (fr) |
PT (1) | PT973392E (fr) |
WO (1) | WO1998038859A1 (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6794511B2 (en) | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6696449B2 (en) * | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
ES2209122T3 (es) | 1997-03-04 | 2004-06-16 | Pharmacia Corporation | Compuestos de acido sulfonil alfa-hidroxi hidroxamico aromatico. |
CN1168709C (zh) * | 1997-11-21 | 2004-09-29 | 厄普约翰药物公司 | 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸的α-羟基、-氨基和卤代衍生物 |
WO2000037433A1 (fr) * | 1998-12-18 | 2000-06-29 | Abbott Laboratories | Inhibiteurs de metalloproteinases matricielles |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
CA2367963A1 (fr) | 1999-03-22 | 2000-09-28 | Darwin Discovery Limited | Derives d'acide hydroxamixe et carboxylique |
KR20020009610A (ko) * | 1999-05-12 | 2002-02-01 | 윌리암스 로저 에이 | 매트릭스 메탈로프로테아제 억제제로서의 히드록삼산 유도체 |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
WO2001038322A1 (fr) | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibiteurs de l'histone deacetylase |
US7569724B2 (en) | 2000-09-29 | 2009-08-04 | Topotarget Uk Limited | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors |
EP1328510B1 (fr) | 2000-09-29 | 2013-11-20 | TopoTarget UK Limited | Composés (e)-n-hydroxy-3-(3-sulfamoyl-phenyl)-acrylamide et leur utilisation thérapeutique |
SG10201603108QA (en) | 2001-06-26 | 2016-05-30 | Amgen Inc | Antibodies To OPGL |
US6683078B2 (en) * | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
FR2827859B1 (fr) | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
JP4606027B2 (ja) * | 2002-04-03 | 2011-01-05 | トポターゲット ユーケー リミテッド | Hdac阻害剤としてのピペラジン結合を有するカルバミン酸化合物 |
US7119203B2 (en) | 2002-04-25 | 2006-10-10 | Pharmacia Corporation | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
GB0226855D0 (en) * | 2002-11-18 | 2002-12-24 | Queen Mary & Westfield College | Histone deacetylase inhibitors |
EP1594459B1 (fr) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Liberation de medicaments a partir d'une composition polymere a gelification rapide |
EP1613269B1 (fr) | 2003-04-04 | 2015-02-25 | Incyte Corporation | Compositions, procedes et kits relatifs au clivage de her-2 |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
NZ550621A (en) * | 2004-03-22 | 2009-11-27 | Southern Res Inst | Nonpeptide inhibitors of matrix metalloproteinases |
WO2005117882A2 (fr) * | 2004-04-20 | 2005-12-15 | Incyte Corporation | Derives d'acide hydroxamique en tant qu'inhibiteurs de metalloproteases |
AU2005260111B2 (en) * | 2004-06-01 | 2011-06-16 | The Scripps Research Institute | Proteomic analysis |
US20050277897A1 (en) * | 2004-06-14 | 2005-12-15 | Ghannoum Ziad R | Handpiece tip |
TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
EP2364975B1 (fr) * | 2008-10-27 | 2013-06-12 | Mitsubishi Tanabe Pharma Corporation | Nouveau dérivé amide et son utilisation comme médicament |
JP5890312B2 (ja) | 2009-10-09 | 2016-03-22 | ザフゲン,インコーポレイテッド | 肥満治療に用いられるスルホン化合物 |
EP2595988B1 (fr) | 2010-07-22 | 2014-12-17 | Zafgen, Inc. | Composés tricycliques et procédés pour les préparer et les utiliser |
JP6058557B2 (ja) | 2011-01-26 | 2017-01-11 | ザフゲン,インコーポレイテッド | テトラゾール化合物ならびにその作製方法および使用方法 |
CN103748094B (zh) | 2011-05-06 | 2016-06-29 | 扎夫根股份有限公司 | 三环磺酰胺化合物及其制备和使用方法 |
KR101979039B1 (ko) | 2011-05-06 | 2019-05-15 | 자프겐 인크. | 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법 |
US9242997B2 (en) | 2011-05-06 | 2016-01-26 | Zafgen, Inc. | Tricyclic pyrazole sulphonamide compunds and methods of making and using same |
CN104892457B (zh) * | 2011-07-25 | 2017-07-28 | 中国医学科学院医药生物技术研究所 | 一种异羟肟酸类衍生物、其药物组合物、制备方法及用途 |
WO2013082458A1 (fr) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Solution de protection de reperfusion et ses utilisations |
CN104169268A (zh) | 2012-01-18 | 2014-11-26 | 扎夫根股份有限公司 | 三环砜化合物及其制备和使用方法 |
US9359369B2 (en) | 2012-01-18 | 2016-06-07 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
BR112015010196A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | métodos de tratar doença do fígado |
KR20150080614A (ko) | 2012-11-05 | 2015-07-09 | 자프겐 인크. | 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물 |
BR112015010225A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos e seus métodos de produção e utilização |
WO2014072214A1 (fr) * | 2012-11-09 | 2014-05-15 | Unilever N.V. | Composition et procédé pour le traitement de substrats |
RU2016148863A (ru) * | 2014-05-14 | 2018-06-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт | Гетероциклические гидроксамовые кислоты в качестве ингибиторов протеин-деацетилазы и двойных ингибиторов протеин-деацетилазы-протеин-киназы и способы их применения |
US10772876B2 (en) * | 2016-03-17 | 2020-09-15 | Xeniopro GmbH | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch |
WO2020006384A1 (fr) * | 2018-06-29 | 2020-01-02 | Loyola University Of Chicago | Inhibiteurs de métalloprotéinase matricielle d'acide hydroxamique carborane et agents pour une thérapie par capture de neutrons par le bore |
CN111217722B (zh) * | 2020-03-06 | 2024-01-02 | 华东理工大学 | 偶氮芳基脲类衍生物及其制备方法和应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148801A (en) * | 1978-07-03 | 1979-04-10 | American Home Products Corporation | 3-[(Chlorophenylsulfonyl)methyl]-1,2,4-oxadiazole-5-carboxylic acid derivatives |
US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
US5103014A (en) * | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
GB2212153B (en) | 1987-11-16 | 1992-01-15 | Squibb & Sons Inc | Phenyl hydroxamic acids |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5527945A (en) * | 1989-02-10 | 1996-06-18 | Basf Aktiengesellschaft | Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom |
ATE159938T1 (de) * | 1990-12-17 | 1997-11-15 | Sankyo Co | Pyrazolderivate mit herbizider wirkung, deren herstellung und verwendung |
ATE150452T1 (de) * | 1992-04-07 | 1997-04-15 | British Biotech Pharm | Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren |
US5376664A (en) | 1992-07-27 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents |
US5646167A (en) | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US5552419A (en) | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
WO1995029892A1 (fr) | 1994-04-28 | 1995-11-09 | The Du Pont Merck Pharmaceutical Company | Derives d'acides hydroxamiques et d'acides amines et leur utilisation comme agents antiarthritiques |
GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
MX9702487A (es) | 1994-10-05 | 1998-04-30 | Darwin Discovery Ltd | Compuestos peptidilo y su uso terapeutico como inhibidores de las metaloproteasas. |
US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
KR19990072009A (ko) | 1995-08-12 | 1999-09-27 | 게리 이. 프리드만 | 메탈로프로티나제 방해제, 그를 포함하는 약제 조성물 및 약제로서의 용도, 그리고 그의 제조방법 및 제조에 유용한 중간체 |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
EP0871439B1 (fr) * | 1996-01-02 | 2004-03-31 | Aventis Pharmaceuticals Inc. | Composes d'acide (aryle, heteroaryle, arylmethyle ou heteroarylmethyle) hydroxamique substitues |
EP0994104A4 (fr) | 1996-06-27 | 2001-09-12 | Ono Pharmaceutical Co | Derives d'aryle (sulfure, oxyde sulfonique et sulfone) et medicaments les contenant en tant que principe actif |
CN1227540A (zh) * | 1996-08-07 | 1999-09-01 | 达尔文发现有限公司 | 具有mmp和tnf抑制活性的异羟肟酸与羧酸的衍生物 |
JP2001516338A (ja) * | 1996-09-27 | 2001-09-25 | ファルマシア・アンド・アップジョン・カンパニー | マトリックスメタロプロテイナーゼ・インヒビターとしてのβ―スルホニルヒドロキサム酸 |
DE69801530T2 (de) * | 1997-01-13 | 2002-05-08 | Fuji Photo Film Co., Ltd. | Wärmeentwickelbares, photoempfindliches Farbmaterial |
JP2000507975A (ja) * | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
EE04150B1 (et) * | 1997-02-27 | 2003-10-15 | American Cyanamid Company | N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül-, -sulfinüül- või -sulfonüül-)-3-asendatud -alküülamiidid, -arüülamiidid või -heteroarüülamiidid kui maatriksmetalloproteinaasi inhibiitorid |
ES2209122T3 (es) | 1997-03-04 | 2004-06-16 | Pharmacia Corporation | Compuestos de acido sulfonil alfa-hidroxi hidroxamico aromatico. |
US20010014688A1 (en) * | 1997-11-14 | 2001-08-16 | Thomas E. Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
-
1998
- 1998-03-04 ES ES98910177T patent/ES2209122T3/es not_active Expired - Lifetime
- 1998-03-04 IL IL13149398A patent/IL131493A/en not_active IP Right Cessation
- 1998-03-04 WO PCT/US1998/004300 patent/WO1998038859A1/fr not_active Application Discontinuation
- 1998-03-04 EP EP98908964A patent/EP0983258A4/fr not_active Withdrawn
- 1998-03-04 CA CA002282318A patent/CA2282318A1/fr not_active Abandoned
- 1998-03-04 CN CN98804575A patent/CN1105114C/zh not_active Expired - Fee Related
- 1998-03-04 US US09/230,209 patent/US6380258B2/en not_active Expired - Fee Related
- 1998-03-04 AU AU66865/98A patent/AU750303B2/en not_active Ceased
- 1998-03-04 KR KR1019997008028A patent/KR20000075946A/ko not_active Application Discontinuation
- 1998-03-04 EP EP98908949A patent/EP0983257A4/fr not_active Withdrawn
- 1998-03-04 CA CA002283145A patent/CA2283145A1/fr not_active Abandoned
- 1998-03-04 KR KR1019997008036A patent/KR20000075954A/ko not_active Application Discontinuation
- 1998-03-04 JP JP53879698A patent/JP2002513407A/ja not_active Abandoned
- 1998-03-04 CA CA002283272A patent/CA2283272A1/fr not_active Abandoned
- 1998-03-04 DK DK98911481T patent/DK0973392T3/da active
- 1998-03-04 PL PL98335732A patent/PL335732A1/xx unknown
- 1998-03-04 JP JP53878098A patent/JP2002515901A/ja not_active Abandoned
- 1998-03-04 EP EP98911481A patent/EP0973392B1/fr not_active Expired - Lifetime
- 1998-03-04 CN CN98804577A patent/CN1253474A/zh active Pending
- 1998-03-04 PT PT98911481T patent/PT973392E/pt unknown
- 1998-03-04 EA EA199900792A patent/EA199900792A1/ru unknown
- 1998-03-04 NZ NZ337326A patent/NZ337326A/en unknown
- 1998-03-04 CA CA002283275A patent/CA2283275A1/fr not_active Abandoned
- 1998-03-04 IL IL13149498A patent/IL131494A/xx not_active IP Right Cessation
- 1998-03-04 IL IL13149598A patent/IL131495A0/xx unknown
- 1998-03-04 BR BR9808214-0A patent/BR9808214A/pt not_active IP Right Cessation
- 1998-03-04 DE DE69819878T patent/DE69819878T2/de not_active Expired - Fee Related
- 1998-03-04 CN CN98804628A patent/CN1254337A/zh active Pending
- 1998-03-04 EP EP98910177A patent/EP0984959B1/fr not_active Expired - Lifetime
- 1998-03-04 AU AU65424/98A patent/AU750130B2/en not_active Ceased
- 1998-03-04 JP JP53798598A patent/JP2002515900A/ja not_active Abandoned
- 1998-03-04 BR BR9808166-7A patent/BR9808166A/pt not_active Application Discontinuation
- 1998-03-04 ES ES98911481T patent/ES2206903T3/es not_active Expired - Lifetime
- 1998-03-04 JP JP53879998A patent/JP2001518081A/ja not_active Abandoned
- 1998-03-04 AT AT98911481T patent/ATE254599T1/de not_active IP Right Cessation
- 1998-03-04 KR KR1019997008037A patent/KR20000075955A/ko not_active Application Discontinuation
-
1999
- 1999-09-02 NO NO19994252A patent/NO315647B1/no unknown
-
2000
- 2000-11-02 HK HK00106978A patent/HK1027806A1/xx not_active IP Right Cessation
-
2001
- 2001-11-29 US US09/997,552 patent/US6656954B2/en not_active Expired - Fee Related
-
2003
- 2003-10-27 US US10/695,278 patent/US20040097487A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1027806A1 (en) | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds | |
EP0983267A4 (fr) | Composes d'acide hydroxamique sulfonamide a cycle amidoaromatique | |
AP2001002240A0 (en) | Sufamato hydroxamic acid metalloprotease inhibitor. | |
WO2001085680A3 (fr) | Composes d'acide hydroxamique, sulfonylaryle ou heteroaryle | |
NZ515197A (en) | Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors | |
GB2303850A (en) | Metalloproteinase inhibitors | |
IL135921A0 (en) | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity | |
CA2333401A1 (fr) | Reduction de la croissance des cheveux a l'aide d'inhibiteurs de metalloproteinases matricielles | |
MX9706380A (es) | Guanidinas de acidos alquenil-carboxilicos sustituidos con fenilo, procedimientos para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como un medicamento que las contiene. | |
CA2268484A1 (fr) | Derives d'acide hydroxamique aryloxyarylsulfonylamino de cyclobutyle | |
YU85403A (sh) | Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora | |
LT2004074A (en) | Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti | |
ZA978400B (en) | Use of inhibitors of the activity of retinoic acid to promote healing. | |
WO2000021508A3 (fr) | Nouvelle utilisation therapeutique de composes a activite beta-3-agoniste | |
MY141460A (en) | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | |
TH66678A (th) | สารยับยั้งเมทัลโลซีนของกรดซัลฟามาโตไฮดรอกซามิค | |
SU1166473A1 (ru) | ДИТИОАЦЕТИЛГИДРАЗОН α -КАМФОРХИНОНА, ПРОЯВЛЯЮЩИЙ ПРОТИВОГИПОКСИЧЕСКУЮ АКТИВНОСТЬ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20070304 |